Publications by authors named "Peter Wung"

Claim this Profile
D
Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.
Denis Poddubnyy, Bhumik Parikh, Dirk Elewaut, Victoria Navarro-Compán, Stefan Siebert, Peter Wung

Arthritis Rheumatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
Daniel Blockmans, Sara K Penn, Arathi R Setty, Wolfgang A Schmidt, Andrea Rubbert-Roth, Peter K Wung

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Peter Wung

Arthritis Res Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Peter Wung

Arthritis Res Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Peter Wung

ACR Open Rheumatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Gerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F Azevedo, Peter Wung

Rheumatol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In-Ho Song, Peter Wung

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib: Mechanism of action, clinical, and translational science.
Mohamed-Eslam F Mohamed, Sumit Bhatnagar, Julie M Parmentier, Priscila Nakasato, Peter Wung

Clin Transl Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Peter Wung

Clin Exp Rheumatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D Inman, Hideto Kameda, Peter Wung

Arthritis Res Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2.
Uta Kiltz, Mitsumasa Kishimoto, Jessica A Walsh, Percival Sampaio-Barros, Manish Mittal, Peter Wung

Rheumatol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
Iain B McInnes, Koji Kato, Marina Magrey, Joseph F Merola, Mitsumasa Kishimoto, Peter Wung

Rheumatol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D Inman, Peter Wung

Ann Rheum Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
Désirée van der Heijde, Atul Deodhar, Walter P Maksymowych, Joachim Sieper, Filip Van den Bosch, Peter K Wung

RMD Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Peter Wung

Lancet· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
François-Xavier Lescure, Hitoshi Honda, Robert A Fowler, Jennifer Sloane Lazar, Genming Shi, Peter Wung

Lancet Respir Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Yannick Allanore, Peter Wung, Christina Soubrane, Corinne Esperet, Frederic Marrache

Ann Rheum Dis· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).
Ganesh Raghu, Luca Richeldi, Bruno Crestani, Peter Wung, Raphael Bejuit

Eur Respir J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Andrea Fava, Peter K Wung, Fredrick M Wigley, Laura K Hummers, Natalie R Daya

Arthritis Care Res (Hoboken)· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Still" ill?
Peter K Wung, Matthew R Pipeling, Fredrick M Wigley

Am J Med· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.
Peter K Wung, Troy Anderson, Kevin R Fontaine, Gary S Hoffman, Ulrich Specks

Arthritis Rheum· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma.
Matthias Holdhoff, Peter K Wung, John D Petronis, Rima Couzi

J Clin Oncol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An atypical complication of atypical pneumonia.
Emmanuel S Antonarakis, Peter K Wung, Daniel J Durand, Ilya Leyngold, David A Meyerson

Am J Med· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutics of Wegener's granulomatosis.
Peter K Wung, John H Stone

Nat Clin Pract Rheumatol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.
Peter K Wung, Janet T Holbrook, Gary S Hoffman, Andrea K Tibbs, Ulrich Specks

Am J Med· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis